Vanguard Global Advisers
TRAW icon

Vanguard Global Advisers’s Traws Pharma TRAW Stock Holding History

Vanguard Global Advisers’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$221 Hold
262
– – ﹤0.01% 3636
2026
Q1 		$479 Buy
+262
New +$492 ﹤0.01% 3660

Other funds holding TRAW

ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Global Advisers's TRAW Position: Q2 2026 in Review

Vanguard Global Advisers held its Traws Pharma (TRAW) position steady in Q2 2026 at 262 shares worth $221. The position accounts for ﹤0.01% of the portfolio, ranked #3636.

Vanguard Global Advisers first reported a position in TRAW in Q1 2026 and has held it in 2 quarters since. The position peaked at $479 in Q1 2026. 30 funds tracked by Wall St. Rank hold TRAW as of Q2 2026.

  • Vanguard Global Advisers held 262 shares of Traws Pharma worth $221 as of Q2 2026.
  • Vanguard Global Advisers left its Traws Pharma share count unchanged in Q2 2026.
  • Traws Pharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3636 holding.
  • Vanguard Global Advisers first reported a position in Traws Pharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Traws Pharma position peaked at $479 in Q1 2026.
  • 30 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.